May. 30 at 5:27 PM
$VNRX [New Profile] The Company SP is down more than 90% over the last 3yrs and coming off an Oversold position at
$1.90. VNRX showed 5X YoY revenue growth to
$1.0M in Q1 with multiple product lines targeting more than
$24B addressable markets. Early detection assays for animals and humans, simple blood tests that catch chronic diseases including sepsis and even cancer(s). Liquidity is a major issue here, with
$3.1M Cash/ST against more than
$42M Total Liabilities,
$13M Current and
$4-5M quarterly burn rate. The Company has rather compelling technology/assets, but requires a partnership to sustain development, product line growth. That (partnership) is what I anticipate here and management (below) has highlighted the same. 50-100% move from this level (IMO) if/where formal agreement is secured to support liquidity position, further develop assets and growth top line.
https://www.stocktitan.net/news/VNRX/volition-rx-limited-announces-first-quarter-2026-financial-results-c73jf3ma655l.html
